Evidence Points to the Value of Neoadjuvant Therapy for NSCLC

Results from the NeoCOAST-2 trial and a comparison of the Checkmate 77T trial and Checkmate 816 trial indicate that treatment of NSCLC with antibody-drug conjugates before and after surgery improves risk of disease recurrence compared with adjuvant therapy alone. More research is needed to understand exactly how PD-L1 expression among patients affects how patients fare, as the gene’s expression improved outcomes in NeoCOAST-2 trial but not in the Checkmate trials.